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Abstract
Myocardium is comprised of a number of cell types. Although most plentiful by volume, 
cardiac myocytes are greatly outnumbered by nonmyocyte cells, the latter constituting 
approximately 70% of all myocardial cells, of which approximately 90% are cardiac fibro-
blasts (CFBs). To maintain the integrity of the cardiac extracellular matrix (ECM) is one 
of the primary functions of cardiac fibroblasts. ECM represents a network structure that 
provides the structural and functional integrity to the heart. Besides that, it also contains 
a high number of cytokines and growth factors with effects on cardiac function and car-
diac cells. Cardiac ECM also mediates the mechanical connection between the cardio-
myocytes, CFBs, and blood. In addition to producing ECM proteins, CFBs also produce 
ECM-regulatory proteins – matrix metalloproteinases (MMPs), which can degrade ECM 
proteins – and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). To date, 
26 MMPs have been cloned and characterized in vertebrates. From these, MMP1, MMP3, 
MMP8, MMP13, MMP2, MMP9, MMP12, MMP28, and the membrane-type MMPs (MT1-
MMP/MMP14) have been identified to be involved in the myocardial remodeling. The 
role of higher MMPs in the cardiovascular system is less well explored.
Keywords: MMPs, heart remodeling, heart failure, acute coronary syndrome, 
atherosclerosis
1. Introduction
The heart is a muscular pump composed of cardiac myocytes and interstitial components. 
Although most plentiful by volume, cardiac myocytes are greatly outnumbered by nonmyo-
cyte cells, the latter constituting approximately 70% of all myocardial cells, of which approxi-
mately 90% are cardiac fibroblasts (CFBs) [1]. Whereas cardiac myocytes and the coronary 
vasculature are central to the contractile function and viability of the myocardium, so too is 
the extracellular matrix, or cardiac interstitium serve as supporting structure. Collagen fibers, 
the major structural proteins of the interstitium, serve several functions showed in Table 1 [2].
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The ECM is crucial to maintain appropriate cardiac integrity and pump function. Conversely, 
disruption of ECM homeostasis is a central factor for cardiac dysfunction, pathologic remod-
eling, and fibrosis following cardiac injury.
Most myocardial collagen fibers consist of collagen types I and III, which (depending on spe-
cies) account for approximately 80% and 10% of collagen in the healthy heart, respectively. 
The nonstructural compartment of the ECM houses a variety of proteins, which are vital for 
ECM plasticity, and can be divided into three major groups: glycoproteins, proteoglycans, 
and glycosaminoglycans [3].
In addition to a fibrillar collagen network, a basement membrane, proteoglycans, and glycosami-
noglycans, the myocardial ECM contains a large reservoir of bioactive molecules. For example, 
the concentration of angiotensin II (ANG II) and endothelin (ET)-1 is over 100-fold higher within 
the myocardial interstitium than in plasma. ECM also acts as a reservoir for growth factors (such 
as transforming growth factor-β), which are stored within the myocardial interstitium in a latent 
form and directly influence myocardial ECM synthesis and degradation. Moreover, mechanical 
stimuli such as stress or strain are transduced through the myocardial ECM to the cardiac myo-
cyte, which in turn would directly affect myocyte growth and ECM remodelation [4, 5].
2. Normal heart interstitium
2.1. Collagens
As mentioned above, collagen is the predominant structural component of the ECM. It has 
been classified into three components:
1. epimysium – the collagenous matrix that lies below the endothelium of the epicardium 
and endocardium and surrounding the entire muscle
2. endomysium – endomysial collagen fibers consist of fibrils that connect adjoining myo-
cytes to one another and to their neighboring capillaries
3. perimysium – surrounding and interconnecting groups of myocytes. It consists of tendon-
like extensions of the epimysium that arborize into a weave to aggregate myocytes into 
myofibers [6].
Scaffold supporting muscle cells and blood vessels
Lateral connections between cells and muscle bundles to govern architecture
Acting as a signal transducer for cell-cell communication modulating cell motility, survival, and cell proliferation
Coordinating the delivery of force, generated by myocytes, to the ventricular chamber
Determinants of diastolic and systolic myocardial stiffness
Serving to resist myocardial deformation and maintaining shape and wall thickness
Table 1. Functions of the collagen matrix in the heart.
The Role of Matrix Metalloproteinase in Human Body Pathologies38
Collagen synthesis and degradation in the healthy heart is an ongoing balanced process. The 
major types of collagen present in the myocardium of the left ventricle are I and III, with type I 
predominating. Type I collagen is the most abundant collagen of the human body, which forms 
large, eosinophilic fibers known as collagen fibers. The COL1A1 gene produces the pro-alpha1 
(I) chain, and pro-alpha2 (I) chain is produced by the COL1A2 gene. Two chains of pro-alpha1 
(I) combine together with one pro-alpha2 (I) chain to make a molecule of type I procollagen. 
These molecules must be processed by enzymes outside the cell. After that, they arrange them-
selves into long, thin fibrils that cross-link to one another in the spaces around cells, which 
leads to the formation of very strong fibers of the mature type I collagen. In humans, collagen 
alpha-1 (III) chain is encoded by the COL3A1 gene located on chromosome 2. Collagen alpha-1 
(III) chain is a precursor for collagen III that is found in extensible connective tissues [7, 8].
Myocytes are surrounded by a basement membrane (BM). The principal structural compo-
nent of the basement membrane is collagen type IV, while collagens I and III are arranged 
in sequential layers of organization of the BM. However, collagen does not only fulfill the 
architectural function. It is also involved in intracellular signal transduction. Via a β1 inte-
grin-dependent mechanism, collagen can inhibit apoptosis and so promotes cell survival 
in vitro. Collagen is also implicated in the induction of proliferation via FAK activation and 
downstream signaling pathways (Src, MEK, PI3-kinase, and p38 MAPK). In addition, col-
lagen participates in cell spreading through p130Cas phosphorylation via FAK-dependent 
and FAK-independent integrin receptor pathways [9, 10]. Finally, collagen plays a key role in 
cell migration through the activation of FAK and PI3-K, leading to elevated Rac1 activity as a 
downstream consequence in activated cell migration [11].
2.2. Cardiac fibroblasts
Cardiac myocytes occupy approximately 75% of normal myocardial tissue volume, but they 
account for only 30–40% of cell numbers. Cardiac fibroblasts (CFBs) have the highest cell 
population in the myocardium, accounting for about two-thirds of the cells.
Fibroblasts (FBs) are present in every tissue in the body [5]. They are of mesenchymal ori-
gin and are morphologically flat and spindle-shaped, with multiple processes. CFBs in the 
myocardium lack a basement membrane, which distinguishes them from all other cells. In 
the past, FBs have been considered for a homogeneous cell population. Over time, though, 
it has become clear that FBs from various tissues have different properties and functions. 
Fibroblasts are found throughout the cardiac tissue, surrounding myocytes and bridging 
“spaces” between myocardial tissue layers, so that, in essence, every cardiomyocyte is closely 
related to a fibroblast in normal cardiac tissue. The primary function of FBs is to produce 
structural proteins that form the extracellular matrix. Under physiological circumstances, this 
is a constructive process. On the other site, hyperactivity of cardiac fibroblasts can result in 
excess production and deposition of ECM proteins that can lead to fibrosis. Fibrosis of the 
myocardium affects the cardiac structure and function in the negative way. Fibroblasts also 
produce a number of cytokines, peptides, and enzymes including matrix metalloproteinases 
(MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs) that directly 
affect the ECM turnover and homeostasis. In turn, as a feedback, function of fibroblasts can 
also be regulated by MMPs and TIMPs [12, 13].
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CFBs can differentiate into myofibroblasts (myoFBs), more mobile and contractile elements 
with a greater synthetic potential to produce ECM proteins. Incentives for this differentiation 
are various stimuli, most commonly myocardial injury. MyoFBs were identified by Gabbiani 
in 1971 [14]. They only appear after cardiac injury and are not found in healthy myocardium. 
Cardiac myoFBs, similar to CFBs, are nonexcitable cells, which express a number of smooth 
muscle cell markers, such as alpha smooth muscle actin (αSMA), smooth muscle myosin heavy 
chain, paxillin, vinculin, and tensin, that are not typically expressed in quiescent CFBs [15].
2.3. Matrix metalloproteinases in the normal heart
MMPs are a family of more than 25 species of zinc-dependent proteases that are synthesized 
as inactive zymogens (pro-MMPs). They are essential for normal tissue remodeling in pro-
cesses such as bone growth, wound healing, and reproduction. Moreover, increased induc-
tion and elaboration of MMPs have been identified to hold biological significance in a number 
of pathological conditions that include cancer, inflammatory disease, and cardiovascular dis-
ease. MMPs are the predominant proteases responsible for degradation of the ECM proteins. 
To date, 26 MMPs have been cloned and characterized in vertebrates. From these, MMP1, 
MMP3, MMP8, MMP13, MMP2, MMP9, MMP12, MMP28, and the membrane-type MMPs 
(MT1-MMP/MMP14) have been identified to be involved in the myocardial remodeling. The 
role of higher MMPs in the cardiovascular system is less well explored [16].
The interstitial collagenase (MMP-1), neutrophil collagenase (MMP-8), and collagenase-3 
(MMP-13) possess high substrate specificity for fibrillar collagens, as well as other ECM pro-
teins such as aggrecan, perlican, versican, and proteoglycans. The important substrates for 
MMP-1 and MMP-13 within the myocardium include the fibrillar collagens such as collagen 
type I and III [17].
The gelatinases (MMP-2 and MMP-9) demonstrate substrate affinity for denatured fibrillar col-
lagen, basement membrane proteins such as collagen type IV, fibronectin, and laminin. MMP-2 
and MMP-9 also exhibit proteolytic activity against elastin and proteoglycans. Past studies 
have demonstrated that MMP-9 is synthesized by myocytes, fibroblasts, and smooth muscle 
cells. Moreover, neutrophils have also been reported to be a potential source of MMP-9 [18].
Stromelysin (MMP-3) degrades all basement membrane proteins, elastin, and proteoglycans.
MMP-7 lacks the hemopexin domain, which seems to be critical in substrate recognition. 
Therefore, MMP-7 has a wide substrate portfolio and possesses proteolytic activity against 
the fibrillar collagens I and III, basement membrane proteins (collagen IV and fibronectin), 
and proteoglycans [19].
MMP-12 (macrophage elastase) has broad substrate specificity for extracellular components 
and is shown to be a key player in tissue remodeling associated with many pathological con-
ditions such as chronic inflammation and fibrosis [20].
During ECM degradation (in physiological ECM turnover or pathological ECM remodeling), 
collagen fibers are degraded into smaller peptides. After that, telopeptides in the N-terminals 
or C-terminals of collagen molecules are cleaved. The propeptide from the carboxy-terminal 
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or the amino-terminal propeptides of collagen type I (PICP, PINP) and both terminals of col-
lagen type III (PIIICP, PIIINP) that uprise during biosynthesis of these collagens can be con-
sidered as biomarkers of collagen synthesis, as they are released in a stoichiometric manner. 
Similarly, the C-terminal or N-terminal telopeptides of collagen type I (CITP, NITP) and type 
III (CIIITP, NIIITP), produced by degradation of these collagens, are considered biomarkers 
of collagen degradation [21].
3. MMPs in heart disease
Matrix metalloproteinases and their inhibitors have a fundamental role in the remodeling of 
the ECM in both normal and pathological conditions. In addition, MMPs have an important 
role in cardiovascular diseases, including acute and chronic heart failure (CHF), acute myo-
cardial infarction, atherosclerosis, and cardiomyopathies.
3.1. MMPs in acute heart failure
Although the relationship between MMPs and chronic heart failure (CHF) has been well 
investigated, we have poor information about changes in the serum levels of MMPs in 
patients with acute heart failure (AHF). In patients with AHF, production of MMPs is affected 
by several mechanisms including changes in hemodynamic conditions and neurohormonal 
and inflammatory factors. Biolo et al. reported that some markers of extracellular matrix turn-
over (MMP-2, TIMP-1, and procollagen type III N-terminal peptide) were elevated in patients 
with AHF syndrome. The increase in ECM turnover may be associated with an acceleration 
of pathological remodeling. The decrease in the concentrations of MMP-2 during the acute 
phase of heart failure may represent the deceleration of myocardial remodeling and maybe 
a better prognosis of AHF [22]. In the study of Shirakabe et al., the serum levels of MMP-2 
were measured on 83 AHF patients before starting treatment (day 1), on day 3 and day 7 after 
admission to the hospital, and before discharge. They found rapid and significant decrease in 
the MMP-2 concentrations on day 3 compared to day 1, whereas the MMP-2 levels were not 
significantly different on day 7 and at predischarge. Authors also evaluated the relationship 
between ΔMMP-2 (defined as the changes in MMP-2 concentrations from day 1 to day 3) and 
HF events including cardiac death, readmission to hospital for HF, and controllable HF. The 
levels of MMP-2 were significantly (p = 0.004) more decreased in the event-free group com-
pared to the group with events mentioned above. The results of multivariate logistic regres-
sion model for predicting HF events found that the specific factor for HF events was ΔMMP-2. 
Rapid decrease in MMP-2 concentration after acute heart failure event thus may be important 
for better clinical outcome in patients with AHF [23].
Hadipurnomo et al. examined samples of 122 consecutive patients with acute coronary syn-
drome (ACS) treated in ICCU of which 47 showed the signs of AHF. The level of MMP-9 
was examined a time at admission in ICCU, before thrombolysis was done. The acute heart 
failure accompanying ACS had Killip II-IV scores. The level of MMP-9 in ACS with AHF was 
significantly higher than in ACS without AHF, with p value <0.001 [24]. Similar results were 
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presented in a study of Jong et al. who investigated the serum concentrations and activities 
of MMP-9 in patients with heart failure developed after AMI. Twenty-eight patients post-
AMI and without heart failure (Killip I, cardiopulmonary compensated) and twenty-seven 
post-AMI patients who developed heart failure (Killip II-III, decompensated) were selected 
to evaluate the serum levels and activities of MMP-9. It was observed that both serum levels 
and activities of MMP-9 significantly increased (P < 0.01) in decompensated group compared 
to compensated group. The highly elevated serum MMP-9 concentration of decompensated 
patients was not related to inflammatory or localized infarct area of myocardium. Authors 
suggest that the increase of MMP-9 levels and activity may be used as a new marker to diag-
nose the development of heart failure in patients post-MI [25]. Levosimendan is calcium sen-
sitizer, cardiotonic agent that binds to troponin C with high affinity. This pharmaceutical 
agent promotes cardiac contractility without increasing myocardial oxygen demand. Tziakas, 
et al. demonstrated that levosimendan significantly reduced MMP-2 levels in patients with 
acute decompensation of chronic heart failure [26].
3.2. MMPs in the chronic heart failure
Essential points in the development and progression of HF include changes in the structure, 
composition, and geometry of the left ventricular (LV) myocardium, which has been generi-
cally termed LV remodeling. Left ventricular remodeling that precedes and occurs along the 
development of HF is strongly associated with adverse clinical outcomes in HF patients with 
systolic dysfunction. Changes in the overall structure and function of extracellular matrix 
directly contribute to the adverse LV remodeling. There are fairly distinct patterns of LV 
remodeling that occur and are dependent on the initial pathophysiological stimulus but, once 
instigated, LV remodeling is an important predictor for the development and progression of 
HF. The activity of MMPs has been shown to be increased in the progression of heart failure. 
The level of MMPs and their induction and activation systems are increased in pathological 
specimens of human heart failure.
As mentioned above, sources of MMPs in the heart are fibroblasts, myocytes, endothelial 
cells, and inflammatory cells, e.g. monocytes that infiltrate the myocardium in several cir-
cumstances. In heart failure, plasma levels of tumor necrosis factor-α (TNF-α) are increased. 
Monocytes stimulated by TNF-α are capable to produce MMP-9. It is supposed that mono-
cytes and other blood elements may serve as carriers of MMP-9, which is synthesized before 
they infiltrate the myocardium. Observation that in reperfusion of myocardium after acute 
infarction, infiltrating neutrophils are the predominant source of MMP-9 and activating 
enzymes supports this hypothesis.
Cyclic strain has been shown to induce a number of MMPs, such as the gelatinase MMP-2. 
In myocardial biopsies performed in patients with LV pressure overload secondary to aortic 
stenosis, increased MMP-2 expression and activity were identified. In patients with LV hyper-
trophy and HF with a history of hypertension, plasma levels of MMP-2 were significantly 
increased compared with age-matched control subjects. For example, in the study of Spinale 
et al., left ventricular myocardial MMP activity (measured by zymography) increased by 
>2-fold in nonischemic dilated cardiomyopathy (DCM) and ischemic DCM when compared 
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with MMP activity in normal hearts. Abundant concentration of MMP-9 was observed in both 
forms of DCM. MMP-2 and MMP-3 activities were increased with nonischemic DCM. On the 
other site, MMP-1 levels were decreased in both forms of DCM [27].
In patients with CHF, elevated serum levels of MMP-1 and TIMP-1 have been observed. This 
finding indicates a predominance of collagenolytic activity, which results in an increase of 
serum concentrations of CITP (type I collagen carboxy-terminal telopeptide), a marker of 
collagen degradation. A report from López et al. shows an increase of the MMP-1/TIMP-1 
ratio (both in tissue and serum samples) in hypertensive systolic heart failure compared with 
hypertensive diastolic heart failure [28]. On the other hand, some other studies analyzed 
human myocardium from explanted hearts from patients undergoing heart transplantation. 
They have found decreased MMP-1 expression and notable increase in TIMP-1 concentra-
tion [29]. Finally, study of George et al. found that MMP-2 but not TIMP-1 is an independent 
predictor of mortality in patients with CHF [30]. In the study of Jordán et al., patients with 
CHF had lower levels of MMP-1 and higher levels of TIMP-1 and TIMP-1/MMP-1 ratio than 
controls. TIMP-1 levels and the TIMP-1/MMP-1 ratio correlated negatively with peak VO2. 
They also described higher baseline peak VE/VCO2, TIMP-1, TIMP-1/MMP-1 ratio values, 
and lower MMP-1 levels in patients who suffered endpoints (total mortality, readmissions 
for heart failure, and cardiac transplantation). On multivariate analysis, VE/VCO2, MMP-1 
levels, and age were the only variables independently related to prognosis of these patients 
[31]. Similarly, detectable plasma levels of MMP-13 were reduced in patients with LV hyper-
trophy and HF [32]. Interestingly, transgenic expression of human MMP-1 in mice (this MMP 
type is absent in rodents) and induction of LV pressure overload resulted in a relative reduc-
tion in myocardial fibrillar collagen content and improved indices of LV function [33]. These 
findings suggest that the loss of normal constitutive levels of certain MMP types, or failure of 
an induction of certain MMP types with LV pressure overload, may facilitate abnormal ECM 
accumulation and adverse myocardial remodeling.
Study of Morishita et al. demonstrated that in patients with heart failure with preserved ejec-
tion fraction (HFpEF), levels of BNP and the MMP-9/TIMP-1 ratio were lower compared to 
those with heart failure with reduced ejection fraction (HFrEF). An imbalance in the MMP/
TIMP ratio and a robust increase in BNP levels reflect advanced ventricular remodeling, dila-
tation, and wall stretching. MMP and TIMP levels were similar in HFrEF and HFpEF patients 
and may represent ongoing myocardial injury and extracellular matrix remodeling before 
an increase in BNP and a decreased ejection fraction are seen. HFpEF is characterized by 
matrix apposition and myocardial stiffening [34]. Similarly, Martos et al. studied hyperten-
sive patients divided into groups according to the presence of HFpEF and phase of diastolic 
function. Serum carboxy-terminal telopeptide of procollagen type I, carboxy-terminal telo-
peptide of procollagen type I, amino-terminal propeptide of procollagen type III, MMP-2, and 
MMP-9 levels were greater in patients with HFpEF than in those without. When controlled 
for age and gender, levels of serum carboxy-terminal telopeptide of procollagen type I, tis-
sue inhibitor of MMP-1, amino-terminal propeptide of procollagen type III, concentrations 
of PICP (carboxy-terminal telopeptide of procollagen type I), and MMP-2 were increased in 
more severe phases of diastolic dysfunction. Within phases of diastolic dysfunction, markers 
of collagen production (such as serum carboxy-terminal telopeptide of procollagen type I, 
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amino-terminal propeptide of procollagen type III) and MMP-2 and MMP-9 were elevated 
in those with HFpEF compared to those without signs of heart failure. Thus, a matrix and 
fibrosis markers such as MMPs may also be an important prognostic markers in HFpEF [35].
On the other hand, many clinical studies have quantified various circulating levels of MMPs 
and TIMPs in patients with HFrEF. MMP-8 levels were decreased in HF patients compared 
to controls [36]. The circulating levels of gelatinases, MMP-2, and MMP-9 have also been well 
characterized in HF patients. MMP-2 levels were elevated in HFrEF patients when compared 
to healthy controls and were correlated with LV volume, fractional shortening, and NYHA 
classifications [37–40]. Furthermore, MMP-2 levels were an independent predictor of mortal-
ity in patients with HFrEF [38]. Similarly, clinical studies have reported elevated circulating 
MMP-9 levels in SHF patients compared to healthy controls [41], but, by contrast, there are 
also reports that there are no differences between circulating levels of MMP-9 in SHF and 
control groups [37]. The discrepancies between these studies are not explained by variations 
in severity, HF etiology, or age. MMP-3 levels were increased in patients with SHF due to 
dilated cardiomyopathy and were correlated negatively with changes in the LV dimensions 
and volume, and independently predictive for cardiac events (death and hospitalization) [42]. 
In addition, MMP-3 levels were increased in patients after acute myocardial infarction who 
developed CHF [43].
3.3. MMPs in acute coronary syndromes
Acute coronary syndrome (ACS) is a term used for a group of conditions due to decreased 
blood flow in the coronary arteries such that part of the heart muscle is unable to act properly 
or dies. ACS is one of the leading causes of cardiovascular death. It includes unstable angina 
(UA), non-ST segment elevation myocardial infarction (NSTEMI), and myocardial infarction 
with ST segment elevation (STEMI) [44]. Most cases of ACS are caused by the erosion or 
rupture of an atherosclerotic plaque, a thickening of the vessel wall in a coronary artery with 
consequential thrombus formation. ACS is one of the leading causes of cardiovascular death, 
and early diagnosis of ACS is important because of the improvement in prognosis follow-
ing timely interventions. It seems that some matrix metalloproteinases are implicated in the 
pathogenesis of cardiovascular diseases. Inflammatory components also appear to be corre-
lated with development of atherosclerosis and ACS [45].
Hamed and Fattah measured levels of MMP-9 as a potential risk factor in 75 patients with ACS 
compared to 25 patients with stable angina (SA) and 20 healthy participants. In this study, 
patients in the SA group had significantly lower MMP-9 levels than those with ACS. Patients 
with ST-elevated myocardial infarction (MI) had highest MMP-9 levels, while in the control 
group, the lowest levels of MMP-9 were found. Patients with ACS having poor disease outcome 
(recurrent ischemic attacks, congestive heart failure, or death) had significantly higher MMP-9 
levels. Cutoff value of MMP-9 equal to 3100 pg./mL was able to discriminate MI from unstable 
angina (UA). The best prognostic utility for MMP-9 was established at 4700 pg./mL [46].
Kai et al. reported that circulating MMP-2 and MMP-9 levels on admission were elevated in 
patients with acute myocardial infarction (AMI) and UA [47]. Inokubo et al. also reported 
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that coronary circulation plasma concentrations of MMP-9 were significantly higher in the 
in-patients with AMI and UA when compared to control subjects. This finding supposes a 
process of active plaque rupture in acute coronary syndrome [48]. Hirohata et al. and Hojo 
et al. also observed increased concentrations of plasma MMP-1 and MMP-2 in patients with 
acute myocardial infarction [49, 50]. In the last ESC guidelines for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation, deter-
mination of concentrations of high-sensitive troponin T in the short “rule-in”/“rule-out” algo-
rithms is recommended in the early diagnostic of ACS [51]. In the ACS, both MMP-9 and 
TnT levels are elevated compared to the control group. But, Kobayashi et al. have shown that 
within 4 h of ACS onset only the plasma level of MMP-9 was markedly increased. By contrast, 
concentrations of TnT were not significantly altered. In addition, MMP-9 concentrations were 
significantly higher in patients within first hours of ACS than in patients with late ACS inde-
pendent of having STEMI or NSTEMI. On the contrary, levels of hs-TnT were significantly 
lower in patients with early ACS than with late ACS. This study indicates that plasma levels 
of MMP-9 increase approximately 80 minutes after the onset of ACS and sustain for 24 h 
thereafter. On the other hand, serum levels of hs-TnT peaked at 12–24 h after ACS onset [52].
The long-term study from Dhillon et al. examined the predictive value for cardiac events 
(death, readmission with HF, or recurrent MI) of MMP-2, MMP-3, and MMP-9 levels in 
patients with acute coronary syndrome in comparison to established markers, e.g. N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) and the Global Registry of Acute Coronary 
Events (GRACE) score. In this study, MMP-2 and MMP-3 were elevated in patients with fatal 
outcome compared to survivors but were similar in patients with CHF or MI. MMP-9 lev-
els were similar across study endpoints. Using Cox proportional hazards modeling, MMP-2 
demonstrated an independent prediction of death with HR 6.60, along with NT-proBNP (HR 
4.62) and the GRACE score (HR 1.03). MMP-3, MMP-9 levels, and log10-troponin I were not 
predictive for negative outcome. The areas under the receiver operating characteristic curves 
were 0.60 and 0.58 for MMP-2 and MMP-3, respectively, compared to 0.82 for NT-proBNP 
and 0.84 for the GRACE score (all statistically significant) for one-year mortality. Kaplan-
Meier analysis showed that MMP-2 concentrations in the highest quartile were associated 
with higher mortality rates (P = 0.006, log rank 12.49). MMP-2 and MMP-3 levels revealed a 
weak association with HF readmission on univariate analysis, which was lost after adjust-
ment for other clinical factors and situations. In this study, none of the MMPs tested predicted 
onset of MI [53].
As mentioned above, significant portion of regulation components for MMP production in 
the myocardium after the myocardial infarction is induced by the local proinflammatory 
cytokines. In an animal model of myocardial injury after AMI, the authors demonstrated 
that a local increase in TNF-α production in the myocardium is directly responsible for the 
increased production of local MMP-9 and MMP-2. This is associated with changes in transi-
tion of integrin isoforms, which can lead to such aggressive collagen dissolution that causes 
an acute myocardial rupture. If this process continues without rupture, heart walls become 
thick and significantly dilated, which leads to decreased function of the ventricle and poor 
survival. However, deletion of the gene for TNF-α through genetic manipulation in the host 
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animal leads to a significant reduction in the concentrations of the inflammatory cytokines, 
which is associated with the reduction in local MMP activation. This results in a significant 
decrease in the incidence of heart wall rupture and a reduction in the subsequent heart size 
and development of heart failure with reduced ejection fraction of the LV [2]. Kelly et al. 
examined the temporal profiles of plasma concentrations of MMP-2 and MMP-9 and their 
relationship with echocardiographic parameters of left ventricle function and remodeling 
in humans after acute myocardial infarction. They showed that higher peak concentrations 
of plasma MMP-9 were associated with the extent of LV remodeling, which led to greater 
impairment of left ventricular function. In contrast, higher plateau levels of MMP-9 in the 
days after acute myocardial infarction were associated with a lesser degree of heart remodela-
tion, and relative preservation of ventricular function [54].
3.3.1. Restenosis
The role of MMPs in iatrogenic postprocedural vasculopathy has also attracted a great deal of 
interest. The development of percutaneous coronary intervention (PCI) has provided a pow-
erful means for treating ischemic heart disease. About 25–40% of patients undergoing PCI 
without a stent implantation have a recurrence of coronary artery disease symptoms within 
6 months because of restenosis at the original site. A combination of events is involved in this 
pathological process, e.g. the migration and rapid growth of medial vascular smooth muscle 
cells, local production of chemocytokines, and other biologically active substances with for-
mation of a characteristic lesion of fibrocellular intimal hyperplasia.
Hojo et al. investigated changes in MMP-2 levels in the coronary circulation after PCI in 
patients with angina pectoris. Plasma MMP-2 levels in the coronary sinus increased signifi-
cantly 4 h after PCI. A positive correlation between concentrations of MMP-2 in the fourth 
hour after PCI and late loss index measured 6 months after PCI was observed. Authors sug-
gested that excessively raised concentrations of MMPs in dilated coronary arteries after PCI 
lead to abnormal vascular remodeling and late restenosis by boosting migration of VSMCs 
and eventual formation of thrombus [55].
3.4. MMPs in atherosclerosis
It is widely accepted that atherosclerosis is promoted by mechanical and/or chemical injury of 
the vascular endothelium. This is followed by transendothelial migration of circulating mono-
cytes from the circulating blood into the intima, where they become activated and produce a 
variety of cytokines, growth factors, and other biologically active substances. Formation of an 
atherosclerotic plaque occurs as a result of cellular migration and local proliferation followed 
by an accumulation of ECM, lipids, and calcium. Degradation of vascular ECM regulated by 
MMP-2 promotes smooth muscle cell migration and early plaque development. During the 
initial period of atherosclerotic plaque development, outward growth produces compensatory 
enlargement of the artery wall that involves matrix remodeling. Hypertension and aging lead 
to decrease of arterial compliance, which correlates with gradual accumulation of collagen 
and loss of elastin. In the latter stages of atherosclerotic process, disruption of the atheroscle-
rotic plaque due to rupture of the fibrous cap or superficial erosion of the endothelium may 
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occur followed by thrombotic complications. These processes (atherosclerotic plaque rupture 
and formation of thrombus) depend on excessive ECM degradation. Neovascularization of 
the atherosclerotic plaque may also play a role in destabilization of the plaque. The angio-
genesis within the plaque is influenced and regulated by MMP activity through interactions 
between proteinases and integrins.
Extreme stage of arterial remodeling due to increased ECM degradation mediated by MMP-2 
and MMP-9 is represented as aneurysm formation [56]. Some previous studies showed that 
lipid-laden macrophages infiltrating human atherosclerotic plaque produce MMP-1 and 
MMP-3. Culture of these macrophages with fibrous caps of human atherosclerotic plaque 
leads to MMP-dependent collagen cleaving [57]. Henney et al. found the presence of MMP-3 
transcripts in atherosclerotic lesions from coronary arteries, which were localized together 
with clusters of lipid-laden macrophages in the shoulder areas of the atherosclerotic plaque 
[58]. Galis et al. reported that normal arteries and atherosclerotic plaque had different origins 
of MMPs. MMP-2 is secreted by VSMCs in all layers of nonatherosclerotic arteries, whereas 
in the atherosclerotic lesions, MMP-1, MMP-3, and MMP-9 production is localized to macro-
phages, VSMCs, and endothelial cells [59]. Some other studies have also reported the expres-
sion of several other MMPs including MMP-1, MMP-2, MMP-7, MMP-9, and MMP-12 in the 
shoulder areas of the plaque [60–62]. The demise of atherosclerotic plaque occurs through 
structural disruption of the arterial wall, which triggers thrombosis, the cause of occlusion 
and the majority of acute vascular events. The discovery of strong local MMP overexpression 
and in situ matrix-degrading activity in the vulnerable shoulders of human atheroma has 
provided a potential mechanistic insight into the process of plaque destabilization through 
matrix weakening by MMPs, especially in the vulnerable shoulders [63]. Resident macro-
phage-derived foam cells, characteristic of unstable plaques, have been identified as a major 
source of MMPs, including MMP-1, MMP-2, MMP-3, MMP-7, and MMP-associated activity 
in human and experimental atherosclerotic lesions [64].
It has been suggested that alternative ways or complementary systems for activation of latent 
MMPs in atherosclerotic plaques may exist. Purified Pro-MMP-2 can be activated in vitro 
by proteolytical activity of thrombin and this mechanism could provide cell-independent 
MMP activation at sites of vascular injury [65]. Another proteolytic-activating mechanism of 
MMP preforms may represent plasminogen cascade. Urokinase-type plasminogen activator 
(uPA) and plasminogen activator inhibitor-1 (PAI-1) can also contribute to the development 
of experimental neointimal lesions after injury and to aortic medial destruction, which was 
demonstrated in u-PA and PAI-1–null mice [66].
3.5. MMPs in cardiomyopathies
Cardiomyopathies (CMPs) are defined by structural and functional abnormalities of the ven-
tricular myocardium that are unexplained by flow-limiting coronary artery disease or abnor-
mal loading conditions. In the past, this group of diseases has been subdivided into primary 
CMP, in which the heart is the only involved organ, and secondary forms, where the cardio-
myopathy represents a manifestation of other systemic disorders. Hypertrophic cardiomy-
opathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness that 
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is not solely explained by abnormal loading conditions [67], or, in other words, hypertrophic 
cardiomyopathy (HCM) is defined morphologically as an unexplained hypertrophy in the 
absence of the reason for such a hypertrophy (e.g. hemodynamic stress). At the histological 
level is HCM characterized by myocyte disarray, fibrosis, and abnormalities of the intramyo-
cardial small vessels. HCM represents a monogenic disease of the heart with an autosomal 
dominant way of heritability and different penetrance. Its prevalence in the general popula-
tion is estimated in the rate of 1/500 [68]. Impaired collagenolysis and an increased deposi-
tion of collagen have been seen in patients with HCM. A significant reduction of MMP-1, 
practically to undetectable levels, was described in the patients with HCM. On the contrary, 
an increase of MMP-2 and MMP-9 concentration was found in these patients [69]. Described 
changes in MMP levels result in augmented ECM turnover, characterized by an increase of 
collagen type I and a shift of collagen I to collagen III production. This shift is not easy to 
explain because collagen I is patently more rigid than collagen III. This situation could be 
a compensatory mechanism due to the increase in wall stiffness [70]. Activity of MMP-2 in 
heart failure with preserved ejection fraction correlates negatively with systolic function 
of left ventricle and its levels are significantly rising with higher NYHA functional class. 
In the study of Noji et al., the plasma concentrations of MMP-2, MMP-3, MMP-9, TIMP-1, 
and TIMP-2 in patients with systolic dysfunction defined as fractional shortening (FS) <25% 
(group A), linked to HCM, in patients with HCM without systolic dysfunction (FS ≥ 25%; 
group B), and in healthy control subjects who were age-matched were measured. The con-
centration of MMP-2 in group A was significantly higher than in group B and the control 
subjects, whereas there was no significant difference between group B and the control sub-
jects. MMP-2 concentrations significantly increased as the NYHA functional class increased 
in patients with HCM. MMP-3 and MMP-9 concentrations did not differ among the 3 groups. 
Both MMP-2 and TIMP-2 correlated significantly with FS and LV dimension, negatively and 
positively, respectively [71].
The best-known cardiac disease with respect to myocardial MMP activity is dilated cardio-
myopathy (DCM). A characteristic feature of the DCM is an increase in left ventricle radius 
to wall thickness, which increases myocardial wall stress. This leads to further dilation and 
closes “circulus vitiosus.” The etiology of DCM can be divided into ischemic (50–70%) and 
nonischemic (30–50%), with the latter phenotype including genetic and acquired causes 
[72]. In Western countries, 20–50% of DCM patients have evidence for familial disease. 
In animal and human studies in dilated cardiomyopathy, an increase in collagen type I 
and III production and deposition has been reported, so the collagen type I/type III ratio 
is constantly increased. As mentioned above, collagen type I is more “rigid” as collagen 
type III, providing more tensile strength and resulting in a stiffer matrix. As the left ven-
tricle wall gets thicker during the progression of DCM, excessive production of collagen 
is considered to be an effort to strengthen the heart wall. More core matrix components 
are overproduced within the DCM-stricken myocardium, including elastin, laminin, and 
tenascin C. Furthermore, in the DCM heart arise a new complex interplay between various 
MMPs and TIMPs. This for example includes the MMPs present within the cardiovascu-
lar tissue (MMP-1, MMP-2, and MMP-9) and all four known TIMPs. Animal studies and 
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models show that the enhanced MMP production and protein abundance occur with the 
initiation of LV dilation, and it might be a very early event in DCM. Progression of DCM is 
characterized by a decrease in MMP activity, due to an increase in TIMPs production [73]. 
In a study by Rouet-Benzineb et al., it was demonstrated that MMP-2 and MMP-9 activi-
ties were increased in DCM. In this study, MMP-2 levels were significantly increased not 
only within the myocardial interstitium, but also in cardiocytes. As showed before, MMP-2 
may also cleave contractile proteins, e.g. myosin. Thus, increased MMP levels within the 
myocardium of patients with DCM may have multiple negative consequences that include 
matrix degradation and proteolytic activation of biologically active signaling molecules 
and degradation of contractile structures and, finally, directly affect myocyte structure and 
function [74].
4. Future directions
Ongoing studies targeting receptors for the ECM components have shown potential for new, 
targeted therapeutics, including several in various stages of clinical trials. Specific ECM pro-
teins interact with cells and play an active role in intercellular signaling to control cell behav-
ior that is critical to the repair or fibrotic process. Effective antifibrotic therapies would be 
a significant contribution in the treatment of some cardiac diseases as well as many other 
fibrotic diseases. Strategies reducing overexpression of MMPs in heart diseases may mod-
ify the development (or the speed of development) of adverse cardiac remodeling and, e.g., 
onset of the heart failure after myocardial infarction. This concept has indeed been proved 
in several basic studies, particularly with the inhibition of MMP-9, which represents one of 
the major MMPs involved in myocardial remodeling. Most of these studies show improve-
ment in ventricular function and a reduction in ventricular size after administration of the 
MMP inhibitors [75]. Unfortunately, administration of various MMP inhibitors led to adverse 
events and number of leading candidates for the therapy have been withdrawn from develop-
ment for this indication because of onset of fibromyalgia side effects in earlier trials attempt-
ing to decrease metastasis in cancer. Pharmacologic strategies affecting upstream signaling 
cascades involved in MMP transcription and regulation can participate in the process of our 
understanding of the complex myocardial remodeling and the specific role of MMPs and 
TIMPs. For example, the use of cytokine inhibition in biological therapy (such as administra-
tion of tumor necrosis factor-α neutralizing proteins) may prove to be useful pharmacological 
tools in order to identify the signaling pathways obligatory for MMP species induction [76].
On the other hand, many of the currently used treatment strategies may already partially 
affect MMP activation pathways as part of their “modus operandi.” For example, part of the 
benefit of treatments such as acetylsalicylic acid or statins may decrease the cytokine and 
inflammatory response and so limit the bioactivity of MMPs.
Tissue engineering may open new avenues to create intelligent scaffolds to support regenera-
tion of diseased or damaged tissue.
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